论文部分内容阅读
目的:评价乌司他丁(UTI)治疗急性左心衰的临床疗效及安全性。方法:将120例急性左心衰的患者随机分为治疗组62例和对照组58例,治疗组在常规抗心衰治疗的基础上给予UTI 10万U溶入0.9%氯化钠(NS)注射液10 mL中缓慢静脉注射,Q8h,对照组在常规抗心衰治疗的基础上给予安慰剂0.9%NS 10 mL缓慢静脉注射,Q8h,观察3天后两组患者的心率(HR)、呼吸(R)、血压(BP)、动脉血氧饱和度(SaO_2)、心衰标志物N末端B型利钠肽原(NT-proBNT)改善情况及患者的平均住院时间和院内死亡率。结果:治疗组HR、R、B P、SaO_2、NT-proBNT改善情况及患者的平均住院时间和院内死亡率均优于对照组(P<0.05)。结论:UTI是辅助治疗急性左心衰安全有效的药物,建议临床推广应用。
Objective: To evaluate the clinical efficacy and safety of ulinastatin (UTI) in the treatment of acute left heart failure. Methods: One hundred and twenty patients with acute left heart failure were randomly divided into treatment group (n = 62) and control group (n = 58). The treatment group was given 0.9% sodium chloride (NS) Injection of 10 mL slow intravenous injection, Q8h, the control group on the basis of conventional anti-heart failure treatment given placebo 0.9% NS 10 mL slow intravenous injection, Q8h, observed three days after the two groups of patients heart rate (HR), respiration R, blood pressure (BP), arterial oxygen saturation (SaO_2) and N-terminal pro-brain natriuretic peptide (NT-proBNT) in patients with heart failure and the average length of hospital stay and hospital mortality. Results: The improvement of HR, R, B P, SaO_2 and NT-proBNT in treatment group and the average length of hospital stay and in-hospital mortality in the treatment group were better than those in the control group (P <0.05). Conclusion: UTI is a safe and effective adjuvant treatment of acute left heart failure, and its clinical application is recommended.